Carisma Therapeutics ( NASDAQ: CARM ) announced that the U.S. FDA has granted Fast Track designation for CT-0525, an ex vivo gene-modified antigen receptor-monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2.
The Phase 1 clinical trial for CT-0525 is an open-label study designed to assess the safety, tolerability, and manufacturing feasibility of CT-0525. Source: Press Release More on Carisma Therapeutics Carisma to cut 37% of workforce, stock falls 8% Seeking Alpha’s Quant Rating on Carisma Therapeutics Historical earnings data for Carisma Therapeutics Financial information for Carisma Therapeutics.
